R$ 5.7
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Biomm S.A. is a biotechnology enterprise based in Brazil. Its diverse product portfolio features pharmaceutical and healthcare solutions, including AFREZZA, a human insulin administered as an inhalation powder, and GLARGILIN, a type of glargine insulin. The company also supplies HERZUMA, a trastuzumab, and CONFORT CARE, a moisturizing foot cream. Biomm S.A. was established in 2001 and maintains its headquarters in São Paulo, Brazil.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.
Data is available to registered users only